they're developed against single

Why popularFlu Vaccines Won't Make Investors Rich

could5 Tiffany and Co Double Heart Necklace and Bangle Set, 2009

a more moderen additidirectly to my transformational technologies portfolio, Medarex, has scored an enormous win. the corporate, at the side of Massachusetts Biologic Laboratory, gets $60 million upfront from Merck for license rights to a monoclonal antibody pparently cures C. difficile infection. they're eligible for an additional $16fivemillion in milestones in addition to royalties.

take into consideratiat the service this corporate has done mankind. C. diff, as hospital diarrhea is known as, is a growing explanation for hospital deaths. althoughmany cases outside of hospitals are never diagnosed, we're aware of it kills no less than 30,000 Americans annually. people who do recover, about nineout of ten, can suffer horribly for months. Bravo to Medarex and everyone who made this breakthrough possible by making an investmentyour money on this very worth effort.

So what does this need to do with swine flu

to this point, swine flu is a minor problem in comparison to C. diff. just one person within the united states has died from the infection. Survival rates, if truth be told, are far upperthan they're for C. diff. Still Tiffany and Co elsa peretti round pendant jewelry, it would worsen, and governments are in search of a vaccine. So, simplywhat are the monetaryopportunities

I see nothing significant within the short run. you can never account for mob psychology though, and there have alin a positionbeen surges in a fewvaccine companies. when it comes to fundamentals Tiffany and Co hearts drop earrings platinum jewelry, however, i don't believe popularflu vaccines are going to make investors rich. the reason being that governments are the actual customers for flu vaccines. directly top of that, vaccines are a longtime industry toyields have a tendency to be driven down by competition.

people who are thinking about playing swings should probably lokinto:

Novavax (NASDAQ: NVAX)
Dynavax (NASDAQ: DVAX)
Hemispherx Biopharma (AMEX: HEB)
BioCryst Pharma (NASDAQ: BCRX)
AVI BioPharma (NASDAQ: AVII)
deCode Genetics (NASDAQ: DCGN)
Crucell (NASDAQ: CRXL)
Vical (NASDAQ: VICL)

this doesn't recommendthere don't seem to be long-term flu-related opportunities. despite the fact that swine flu doesn't turn out to be a huge pandemic, influenza is a major international problem that drains resources and lives. the arena fitnessOrganization, estimates that duringfluenza infects fiveto one5% of the arena's population in a popularyear. This ends up in 250,000 to five00,000 deaths. The WHO and the middles for Disease Control and stopion are, in fact, concerned concerning the possibility of a huge global pandemic. Medical science has progressed significantly since 1918, when the "Spanish flu" killed upward of five0 million people; however it's still a major illness.

at this time, the pinnaclelines generated by the flu are largely about looking to trace and prevent its progress. Today, that is terribly difficult. Tlisted here are, however, solutions at the horizon.

I've written before about biochip sensors. These are a real transformational technology. Last year Tiffany and Co atlas cufflinks jewelry, agricultural losses of hundreds of millions of greenbacks were due to the lack to quickly locate the source of a salmonella infection. what's wanted, and can arrive within the not-so-distant future Tiffany and Co icons lock charm bracelet jewelry, are sensors that coulddetect disease pathogens cheaply and that instantaneously. Think Star Trek tricorders...

And we're getting close. EETimes is reporting that CombiMatrix Corp. has made biochips that may be programmed to spot any known flu type. CombiMatrix says its microarray can also be updated for brand spanking new influenzas in not up to an afternoon and will deliver test ends up in barely 4hours.

slightly bit extraout are even bigger benefitopportunities. Specifically, we're taking a look at is an finishto exactflu vaccines.

Pandemic influenzas emerge from a sudden amendmentwithin the flu virus against which there is not any immunity. Vaccines are the primaryremainof flu prevention, however they have got two key limitations. First, they're developed against single, known flu strains. Therefore, they may also be ineffective against new strains. Second, vaccines are produced employinga lengthy process requiring incubation in chicken eggs. New flu vaccines take months or years to stockpile.

Tlisted here are general antiviral medications approved to regard influenza. Influenza deadly disease strains, however, can also become immune to those medications. because of this, scientists want to RNA interference for a brand spanking new way to stoping flu viruses.

i do know of no less than two companies which were engaged within the seek for an RNAi flu cure. the prospective good thing about RNAi antiviral therapeutics is that RNAi will be able for use to impress an immune response that forestalls replication of all influenza deadly diseasees, new or old. Stockpiling of an efficient RNAi treatment can be possible prematudependof an international pandemic and should well be used for routine flus to boot. Moreover, whoever produces the therapy would have an indicationificant benefitpotential. Vaccines are the primaryremainof flu prevention, however they have got two key limitations.